Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S100A9 | P06702 | 2/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791104 | 0.85 | MAPT (0.48) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL28532759 | 0.85 | AAK1 (0.34) | PIK3CGPI4KAPIK3CDMEN1POLB | |
| SCHEMBL29556703 | 0.83 | PIK3CD (0.52) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL114826 | 0.83 | PIK3CD (0.52) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| Ammonia Solution, Strong SCHEMBL28553362 | 0.82 | PIK3CD (0.51) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL17969358 | 0.81 | HPGD (0.44) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 | |
| SCHEMBL21513802 | 0.80 | PRKDC (0.38) | PIK3CGPI4KAPIK3CDMEN1KMT2A | |
| SCHEMBL29629172 | 0.80 | PRKDC (0.38) | PIK3CGPI4KAPIK3CDMEN1KMT2A | |
| SCHEMBL15652790 | 0.80 | PIK3CG (0.42) | PIK3CGPI4KAPIK3CDPIK3CAPIK3CB | |
| SCHEMBL16913931 | 0.79 | PIK3C3 (0.52) | PIK3CGPIK3CDPIK3CAPIK3CBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2167092-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | PIK3CG 21/4885PI4KA 2/4885PIK3CD 14/4885 |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | PIK3CG 21/4885PI4KA 2/4885PIK3CD 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.